ArticleFrontiers in neuroscience2013
Reward learning as a potential target for pharmacological augmentation of cognitive remediation for schizophrenia: a roadmap for preclinical development.
Article in Frontiers in neuroscience, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 26 citations in OpenAlex.
- Neural Circuitry of Salience and Reward Processing in Psychosis.Biological psychiatry global open science · 2023Review
- Galvanic Skin Response Features in Psychiatry and Mental Disorders: A Narrative Review.International journal of environmental research and public health · 2022Review
- Oxytocin improves probabilistic reversal learning but not effortful motivation in Brown Norway rats.Neuropharmacology · 2019Article
- Nicotine improves probabilistic reward learning in wildtype but not alpha7 nAChR null mutants, yet alpha7 nAChR agonists do not improve probabilistic learning.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology · 2018Article
- The effects of early life stress on reward processing.Journal of psychiatric research · 2018Review
- Relationship between effortful motivation and neurocognition in schizophrenia.Schizophrenia research · 2018Article
- Blockade of dopamine DJournal of psychopharmacology (Oxford, England) · 2017Article
- Electroacupuncture attenuates learning and memory impairment via activation of α7nAChR-mediated anti-inflammatory activity in focal cerebral ischemia/reperfusion injured rats.Experimental and therapeutic medicine · 2017Article
- Preclinical Models to Investigate Mechanisms of Negative Symptoms in Schizophrenia.Schizophrenia bulletin · 2017Review
- The effects of reduced dopamine transporter function and chronic lithium on motivation, probabilistic learning, and neurochemistry in mice: Modeling bipolar mania.Neuropharmacology · 2017Article
- GlyT-1 Inhibition Attenuates Attentional But Not Learning or Motivational Deficits of the Sp4 Hypomorphic Mouse Model Relevant to Psychiatric Disorders.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2015Article
- Dopamine physiology in the basal ganglia of male zebra finches during social stimulation.The European journal of neuroscience · 2015Article
- Developing treatments for cognitive deficits in schizophrenia: the challenge of translation.Journal of psychopharmacology (Oxford, England) · 2015Review
- Identifying cognitive remediation change through computational modelling--effects on reinforcement learning in schizophrenia.Schizophrenia bulletin · 2014Article
- Cognitive training in mental disorders: update and future directions.The American journal of psychiatry · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
rationaleImpaired cognitive abilities are a key characteristic of schizophrenia. Although currently approved pharmacological treatments have demonstrated efficacy for positive symptoms, to date no pharmacological treatments successfully reverse cognitive dysfunction in these patients. Cognitively-based interventions such as cognitive remediation (CR) and other psychosocial interventions however, may improve some of the cognitive and functional deficits of schizophrenia. Given that these treatments are time-consuming and labor-intensive, maximizing their effectiveness is a priority. Augmenting psychosocial interventions with pharmacological treatments may be a viable strategy for reducing the impact of cognitive deficits in patients with schizophrenia.
objectiveWe propose a strategy to develop pharmacological treatments that can enhance the reward-related learning processes underlying successful skill-learning in psychosocial interventions. Specifically, we review clinical and preclinical evidence and paradigms that can be utilized to develop these pharmacological augmentation strategies. Prototypes for this approach include dopamine D1 receptor and α7 nicotinic acetylcholine receptor agonists as attractive targets to specifically enhance reward-related learning during CR.
conclusionThe approach outlined here could be used broadly to develop pharmacological augmentation strategies across a number of cognitive domains underlying successful psychosocial treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.